The company claims that the drug is the first and only factor IX
therapy that provides high-level protection with up to 14-day dosing in appropriate patients.
The company has submitted an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) to conduct a Phase 2a study of its long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
1 September 2014 - Canadian biological diagnostic and research products maker Affinity Biologicals Inc said Friday it had recently introduced a new range of plasmas, including the Factor VIII Deficient and the Factor IX
Deficient plasmas, in Canada and Europe.
29 May 2014 - Canadian biological diagnostic and research products maker Affinity Biologicals Inc said Thursday it had recently launched four Visulize ELISA Kits that are able to quantitatively and qualitatively evaluate Factor VIII, Factor IX
, Factor XI and TAFI antigens in human plasma samples.
Paradigm 2 is a multi-centre, blinded study aimed at evaluating the safety and efficacy of the glycopegylated recombinant factor IX
as on-demand or prophylactic treatment against haemophilia B.
Factor IX-CTP demonstrated significantly longer duration of clotting activity in haemophilic mice and bleeding episodes were significantly shorter and less intense compared with commercially available factor IX
CSL Behring, a plasma protein biotherapeutics companies, has started the patient enrollment in pivotal paediatric Phase III haemophilia B study of recombinant fusion protein linking coagulation factor IX
with recombinant albumin, it was reported yesterday.
AMT said that its haemophilia B programme, which consists of an adeno-associated viral (AAV) vector containing the human factor IX
gene, is being investigated in a Phase I/II study conducted by St.
AMT's haemophilia B programme, which consists of an adeno-associated viral (AAV) vector containing the human factor IX
gene, is being investigated in a Phase I/II study conducted by St Jude's Children's Research Hospital (Memphis, US) and University College London (UK).